China Antibody to Sell Suzhou Biologics Manufacturing Base to Yilian Bio for $39.1 Million

China Antibody (03681.HK) said it has signed a sale and purchase agreement with Yilian Bio to sell its Suzhou biologics manufacturing base for 280 million yuan ($39.1 million), according to Jiemian News. The facility was built for commercial-scale production of large-molecule biologics and is ready for use. China Antibody said the site’s net book value was about 336 million yuan as of June 30, 2026, and it expects to recognize an estimated one-off non-operating loss of about 56.341 million yuan from the disposal. Net proceeds will be used for pipeline R&D, clinical studies and general working capital. The company’s shares fell for two sessions after the announcement, closing at HK$1.140 on July 8, down 0.87%, with a market capitalization of about HK$1.581 billion. Yilian Bio, founded in 2020 and focused on antibody-drug conjugates (ADCs), has signed licensing deals with partners including Fosun Henlius, Zai Lab, BioNTech and Roche. In May 2026, Yilian’s lead program YL201 met its primary endpoint in an interim analysis of a domestic Phase 3 pivotal study in nasopharyngeal carcinoma, and Roche obtained ex-China rights in January 2026 with an upfront payment and near-term milestones totaling $570 million, the report said.